1. Volume 38, Issue 1, Pages 51-58 (January 2003)
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial 
Antoni Mas, Juan Rodés, Lourdes Sunyer, Luı́s Rodrigo, Ramon Planas, Victor Vargas, Lluı́s Castells, Dolores Rodrı́guez-Martı́nez, Conrado Fernández-Rodrı́guez, Ignasi Coll, Albert Pardo 
Journal of Hepatology 
Volume 38, Issue 1, Pages (January 2003)
DOI: /S (02)

2. Fig. 1
Time course of the HE grade and treatment effect in cirrhotic patients with grade I–III HE receiving treatment with rifaximin (1200 mg/day) or lactitol (60 g/day). Values are expressed as mean grade (SD). (*) Statistical difference between groups, P=0.012; (**) differences between mean post-treatment grade and basal mean grade, P= in both groups.
Journal of Hepatology  , 51-58DOI: ( /S (02) )

3. Fig. 2
Changes occurring in the PSE index in cirrhotic patients with grade I–III HE following 5–10 days treatment with rifaximin (1200 mg/day) or lactitol (60 g/day). Values are expressed as mean grade (SD); n.s.=0.05 level; (*) P values versus basal mean values, P= in both groups; (**) significant comparison between groups, P= in favor of the rifaximin group.
Journal of Hepatology  , 51-58DOI: ( /S (02) )